Searchable abstracts of presentations at key conferences in endocrinology

ea0099p245 | Calcium and Bone | ECE2024

Education, and early retirement in patients with hereditary hypophosphatemia compared to controls – a retrospective Danish register study

Beck-Nielsen Signe , Johansen Ulla Ege , Hansen Rikke Faergemann , Gleisner Jennifer , Williams Angela

Background: Hereditary hypophosphatemia (HH) are rare diseases, characterized by excessive renal phosphate wasting and inappropriately low 1,25-dihydroxy-vitamin D causing hypophosphatemia. In children, the disease manifests as rickets and osteomalacia, in adults osteomalacia. Complications from the disease appear with increasing age, in adults characterized by pain, arthrosis, persisting deformities of long bones if not corrected during childhood causing compromised functions...

ea0025p8 | Bone | SFEBES2011

Thyrostimulin expression and signalling in the skeleton

Bassett J H Duncan , Hernandez Rebecca , Combs Charlotte , Spek Anne van der , Yu Ming , Williams Allan , Murphy Elaine , Boyde Alan , van Zeijl Clementine J J , Boelen Anita , Williams Graham R

Hypothyroidism and thyrotoxicosis have detrimental effects on skeletal development and adult bone strength. These effects result from thyroid hormone actions in bone, although a direct role for TSH in osteoblasts and osteoclasts was postulated following analysis of TSH receptor (TSHR) null mice. This hypothesis remains controversial as other studies failed to demonstrate osteoblast or osteoclast responses to TSH in vitro. Thyrostimulin is a heterodimeric glycoprotein ho...

ea0077p50 | Metabolism, Obesity and Diabetes | SFEBES2021

Lipocalin 2, a mediator or marker of adipocyte dysfunction?

Parenti Cristina , Lad Nikita , Williams C Neil , Sharpe Graham R , Nelson Carl P , Murphy Alice M , McTernan Philip G

Background: Lipocalin 2 (NGAL) is considered a pro-inflammatory adipokine. Noting the conflicting reports as to the role of Lipocalin 2 in metabolic disease, it remains unclear whether an acute or chronic state affects its impact on adipocyte function. In an attempt to address this our current studies investigated for the first time in humans, whether Lipocalin 2 in abdominal subcutaneous adipose tissue (AT) may influence mitochondrial function and browning of adipocytes, as c...

ea0077p176 | Metabolism, Obesity and Diabetes | SFEBES2021

Asprosin impact on mitochondrial metabolism in obese adipose tissue, a tale of two depots?

Lad Nikita , Murphy Alice M , Parenti Cristina , Nelson Carl P. , Williams Neil C. , Sharpe Graham R. , McTernan Philip G.

Background: In an obese state, pro-inflammatory adipokines can lead to mitochondrial dysfunction and reduced brown adipocytes properties in white adipocytes (BRITE adipocytes), all of which contribute to the pathogenesis of obesity and type 2 diabetes mellitus (T2DM). A recent novel adipokine, asprosin, that influences appetite and glucose homeostasis, appears to drive inflammation in obesity. However, asprosin expression in human adipose tissue (AT) depots, its impact on mito...

ea0078OC6.1 | Oral Communications 6 | BSPED2021

Novel dominant negative GH receptor variants provide important insights into GH receptor physiology

Andrews Afiya , Cottrell Emily , Maharaj Avinaash , Ladha Tasneem , Williams Jack , Metherell Louise A , McCormick Peter J , Storr Helen L

Background: Growth hormone insensitivity (GHI) is a continuum defined by normal/elevated growth hormone (GH), low IGF-I levels and growth restriction. Non-classical/mild-moderate GHI is poorly characterised and is frequently underdiagnosed. Heterozygous dominant negative (DN) gene variants located in the regions encoding the intracellular/transmembrane domains of the GH receptor cause a ‘non-classical’ GHI phenotype.Hypothesis/Objective: Detail...

ea0081ep87 | Adrenal and Cardiovascular Endocrinology | ECE2022

Managing Immune checkpoint inhibitors and adrenal insufficiency in acute setting

Bashir Mahamud , Ramachandran Kirtanya , Volmy Rebecca , Williams Alexanderia , Elonu Akunna , Elekwa Gloria , Fahal Lamis , Rehmani Hassan , Roy Homagni , Mlawa Gideon

The introduction of immune checkpoint inhibitors (ICIs) in clinical management of cancer has had an undeniable impact in management of cancer patients. Currently there are several ICIs are used across Europe including but not limited to, pembrolizumab, atezolizumab, and ipilimumab. Even though their clinical efficacy is reputable, they have the potential of causing serious immunotherapy-related adverse events’ (irADRs) in several organ systems including endocrine organs. ...

ea0082oc1 | Oral Communications | SFEEU2022

Genetic analysis of patients with undiagnosed short stature identified novel dominant negative GH receptor variants which provide important insights into GHR physiology

Andrews Afiya , Cottrell Emily , Maharaj Avinaash , Ladha Tasneem , Williams Jack , A Metherell Louise , J McCormick Peter , Storr Helen L

Case history: Two unrelated male patients were referred for evaluation of short stature. The first patient aged 16.5 years, had a birth weight of 2.6 kg at term (BWSDS -2.4), height 153 cm (HSDS -3.2) at referral and normal BMI SDS of 0.6. He had early postnatal hypoglycemia, which was conservatively managed, but no other significant clinical history. He had relative macrocephaly and disproportionate short stature. His mother was also short with a similar phenotype (height 147...

ea0085p46 | Pituitary and Growth 1 | BSPED2022

A rare heterozygous IGFI variant impairing IGF-I cleavage and causing postnatal growth failure: a novel disease mechanism offering insights into IGF-I physiology

Cottrell Emily , Andrews Afiya , Williams Jack , Chatterjee Sumana , Edate Sujata , Metherell Louise A. , Hwa Vivian , Storr Helen L.

Background: Pathogenic IGFI gene mutations causing childhood growth failure are extremely rare. Only five autosomal recessive mutations, one IGFI copy number variant and two heterozygous frameshift mutations are reported. Heterozygous missense IGFI mutations haven’t previously been described.Objectives: To identify and functionally characterise a novel missense IGFI variant in a patient with postnatal growth failu...

ea0086p69 | Metabolism, Obesity and Diabetes | SFEBES2022

The effect of novel adipokine asprosin on mitochondrial function in human airway epithelial cells

Lad Nikita , Murphy Alice M , Parenti Cristina , Williams Neil C , Nelson Carl P , Sharpe Graham R , McTernan Philip G

Background: Asprosin is a novel adipokine involved in appetite and glucose regulation. During obesity, circulating asprosin is increased, which leads to increased inflammation and can disrupt cellular functions such as mitochondrial respiration. Asthma is a comorbidity of obesity, with both diseases sharing an inflammatory profile and mitochondrial dysfunction. This study investigated the molecular links between asthma and obesity, by exploring whether asprosin causes mitochon...

ea0089b10 | Basic Science | NANETS2022

Inhibition of Estrogen Receptor Alpha Radiosensitizes Neuroendocrine Tumors

Schwarz Jason L. , Williams Jelani K. , Lakiza Olga , Kron Stephen J. , Weichselbaum Ralph R. , Keutgen Xavier M.

Background: The use of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs) is increasing, but PRRT remains palliative at this time. Estrogen (E2) has been extensively linked to cellular proliferation and DNA repair in other cancers. Our aim is to determine whether NET cells are similarly affected by estrogen and whether inhibition of estrogen receptor alpha (ESR1) increases radiosensitivity of NET cells, which could improve PRRT response.<p class=...